Vaxcyte, Inc. (NASDAQ:PCVX) CEO Sells $1,602,300.00 in Stock

Vaxcyte, Inc. (NASDAQ:PCVX) CEO Grant Pickering sold 15,000 shares of the company’s stock in a transaction that occurred on Friday, November 1st. The stock was sold at an average price of $106.82, for a total value of $1,602,300.00. Following the completion of the transaction, the chief executive officer now owns 435,219 shares of the company’s stock, valued at $46,490,093.58. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Grant Pickering also recently made the following trade(s):

• On Monday, October 7th, Grant Pickering sold 7,098 shares of Vaxcyte stock. The stock was sold at an average price of $109.21, for a total transaction of $775,172.58.
• On Friday, August 23rd, Grant Pickering sold 15,000 shares of Vaxcyte stock. The shares were sold at an average price of $78.98, for a total transaction of $1,184,700.00.

Vaxcyte Stock Down 3.2 %

NASDAQ PCVX opened at $104.07 on Thursday. Vaxcyte, Inc. has a 52 week low of $46.16 and a 52 week high of $121.06. The firm has a market capitalization of $11.62 billion, a price-to-earnings ratio of -22.62 and a beta of 1.01. The company has a fifty day moving average of $110.06 and a two-hundred day moving average of $86.69.

Vaxcyte (NASDAQ:PCVX) last released its quarterly earnings results on Tuesday, November 5th. The company reported ($0.83) EPS for the quarter, topping analysts’ consensus estimates of ($1.10) by $0.27. During the same quarter in the previous year, the firm earned ($0.91) EPS. Equities research analysts anticipate that Vaxcyte, Inc. will post -4.33 EPS for the current year.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on the company. BTIG Research raised their price objective on Vaxcyte from $98.00 to $160.00 and gave the company a “buy” rating in a research report on Tuesday, September 3rd. Needham & Company LLC reaffirmed a “buy” rating and issued a $140.00 price objective on shares of Vaxcyte in a research note on Wednesday. Cantor Fitzgerald reiterated an “overweight” rating on shares of Vaxcyte in a research report on Wednesday. Bank of America boosted their price target on shares of Vaxcyte from $101.00 to $140.00 and gave the stock a “buy” rating in a research report on Wednesday, September 4th. Finally, Mizuho increased their price objective on shares of Vaxcyte from $113.00 to $163.00 and gave the company an “outperform” rating in a research report on Tuesday, September 10th. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $147.50.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the business. Riverview Trust Co bought a new stake in shares of Vaxcyte during the 3rd quarter worth approximately $27,000. Fifth Third Bancorp purchased a new stake in Vaxcyte in the second quarter worth $35,000. Fidelis Capital Partners LLC bought a new stake in shares of Vaxcyte during the first quarter worth $37,000. Blue Trust Inc. boosted its stake in shares of Vaxcyte by 33.5% during the third quarter. Blue Trust Inc. now owns 371 shares of the company’s stock valued at $42,000 after purchasing an additional 93 shares during the period. Finally, J.Safra Asset Management Corp grew its holdings in shares of Vaxcyte by 649.4% in the second quarter. J.Safra Asset Management Corp now owns 607 shares of the company’s stock worth $46,000 after purchasing an additional 526 shares during the last quarter. Institutional investors own 96.78% of the company’s stock.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.